🏆 Deal of the Week · CW 26/2022
MiroBio raised USD 97 million in a Series B financing round in June 2022; the post-money valuation was not disclosed. The round was led by Medicxi, with participation from six additional life-science investors.
MiroBio raises $97 million in Series B financing — key deal facts
| Company | MiroBio raises $97 million in Series B financing |
| Founded | 2019 |
| Headquarters | Oxford, United Kingdom |
| Amount raised | USD 97M |
| Valuation | Valuation Remains Undisclosed |
| Round | Series B |
| Investors | Advent Life Sciences (https://www.adventls.com/) Medicxi (https://www.medicxi.com/) Monograph Capital (https://monograph.bio/) OrbiMed (https://www.orbimed.com/) Oxford Sciences Innovation (https://oxfordscienceenterprises.com/) Samsara BioCapital (https://www.samsaracap.com/) SR One (https://www.srone.com/) |
| Sectors | Biotechnology |
Who invested in MiroBio raises $97 million in Series B financing?
The syndicate comprised Advent Life Sciences, Medicxi, Monograph Capital, OrbiMed, Oxford Sciences Innovation, Samsara BioCapital, and SR One. The mix is notable for combining Oxford-linked institutional backing through Oxford Sciences Innovation with established transatlantic healthcare specialists such as OrbiMed and SR One, reflecting broad conviction across both European and US life-science capital markets.
What does MiroBio raises $97 million in Series B financing do?
MiroBio is a UK-based biotechnology company founded in 2019, headquartered in Oxford, United Kingdom. The company develops checkpoint agonist antibody candidates designed to restore immune tolerance in autoimmune diseases. Its lead programs are MB272, a BTLA agonist, and MB151, a PD-1 agonist, both precision-engineered to selectively suppress pathological immune activity. The company's scientific foundation draws on research by Simon Davis and Richard Cornall from the University of Oxford.
MiroBio raises $97 million in Series B financing valuation & multiples
No existing multiples analysis was provided for this deal. Valuation benchmarking for clinical-stage biotechnology companies at the Series B stage typically references revenue-based or pipeline-adjusted metrics rather than conventional EV/Sales or EV/EBITDA multiples, given pre-revenue status. Investors seeking sector-level valuation context are encouraged to explore the relevant biotechnology sector multiples pages on DealMatrix.
Explore the benchmarks: Series B.
Frequently asked questions
How much did MiroBio raise in its Series B?
MiroBio raised USD 97 million in its Series B financing round, closed in June 2022.
What is MiroBio's valuation?
MiroBio's post-money valuation following its Series B round was not publicly disclosed.
Who invested in MiroBio's Series B?
The Series B was led by Medicxi, with co-investors Advent Life Sciences, Monograph Capital, OrbiMed, Oxford Sciences Innovation, Samsara BioCapital, and SR One.
When was MiroBio founded and where is it based?
MiroBio was founded in 2019 and is headquartered in Oxford, United Kingdom.
Source: original announcement — read the full report.